Recent Updates
Recently added Catalysts
INFU

InfuSystem Holdings, Inc. 31700 Research Park Drive Madison Heights, MI 48071 248-291-1210 FOR IMMEDIATE RELEASE Monday

Key Takeaway: InfuSystem Holdings, Inc. 31700 Research Park Drive Madison Heights, MI 48071 248-291-1210 Monday, May 13, 2013 INFUSYSTEM HOLDINGS, INC. REPORTS THIRD STRAIGHT QUARTERLY PROFIT Company Continues To Improve Liquidity Position MICHIGAN, May 13, 2013 InfuSystem Holding

Full Press Release Details

InfuSystem Holdings, Inc.
31700 Research Park Drive
Madison Heights, MI 48071
248-291-1210
Monday, May 13, 2013
INFUSYSTEM HOLDINGS, INC. REPORTS
THIRD STRAIGHT QUARTERLY PROFIT
Company Continues To Improve Liquidity Position
MICHIGAN, May 13, 2013 InfuSystem Holdings, Inc. (NYSE MKT: INFU) ( InfuSystem or the Company ), a leading national provider of infusion pumps and related services for the healthcare industry in the United States,
today reported its third consecutive quarter of profitability in the first quarter ending March 31, 2013.
the first quarter was $0.1 million, equal to $0.00 per diluted share, compared to a $0.9 million net loss, or $0.04 loss per diluted share, in the prior year period. Gross profit for the three months ending March 31, 2013, was $10.4 million,
consistent with the same prior year period.
Our industry in general and InfuSystem in particular are well-positioned
for continued growth, said Eric Steen, who joined the Company as Chief Executive Officer on April 1, 2013. We are firmly committed to organic growth as a means to further strengthen our position in a highly competitive environment.
We remain vigilant about managing costs, and will seek to further increase free cash flow and reduce debt. Finally, as evidenced by our recent hiring of an accomplished Chief Information Officer, we will use technology to increase connectivity with
all stakeholders especially patients, who are number one priority, he concluded.
Revenues in the first quarter
of 2013 were $14.7 million, up 2% from $14.3 million in the first quarter of 2012. The increase in revenues is primarily related to the addition of larger customers, increased penetration into existing customer accounts, continuation of the revision
to claims processing guidelines by a major group of third-party payors and a one-time delay in billing to certain payors caused by the requirement of additional paperwork.
SG&A decreased to $7.4 million from $9.0 million, down approximately 18%, when compared
to the first quarter of 2012. The decrease was primarily attributed to prior year costs of $1.5 million pertaining to the special meeting, changes in the composition of the Board of Director s, and retention payments made to key employees in
connection with the change in senior management.
Other expenses were consistent for the three months ended March 31,
2013 compared to the similar period in 2012; however the breakdown included $0.3 million of additional interest expense due to the cost of the new debt facility. This was offset by a one-time cash receipt of $0.3 million related to a mutual
We are very pleased to have further strengthened the balance sheet, especially reducing total debt by
$2.8 million during the first quarter of 2013 , said Jonathan P. Foster, Chief Financial Officer.
Gross profit for the three months ended March 31, 2013 was $10.4 million, which was consistent with the same period in the prior
year. It represented 71% of revenues in the current period compared to 73% in the prior year. The decrease in the gross margin as a percentage of revenue in 2013 was primarily related to an increase in connectivity costs with our customers.
Selling and marketing expenses were $2.4 million compared to $2.7 million for the three months ended March 31, 2012. The
decrease in selling and marketing expenses was mainly attributed to lower travel, entertainment and salaries.
months ended March 31, 2013, general and administrative expenses were $5.0 million compared to $6.3 million for the same prior year period. General and administrative expenses have decreased from 44% to 34% of revenues for the first quarter of
2013 compared to the same period in the prior year. The decrease was primarily attributed to prior year costs of $1.5 million pertaining to the special meeting, changes in the composition of the Board of Directors, and retention payments to key
employees during the major change in senior management. These prior year charges were offset by $0.3 million of expenses during the three months ended March 31, 2013 due primarily to fees related to the CEO search, the final Severance Payment
made to the former CEO and one-time payments to a Board member (the Transition Costs ).
Adjusted EBITDA was $3.7
million for the first quarter of 2013 compared to $3.4 million in 2012. The Company utilizes Adjusted EBITDA as a means to measure its operating performance. A reconciliation from Adjusted EBITDA, a non-GAAP measure, to net income can be found in
Net cash provided by operations for the three months ended March 31, 2013 was $1.6 million compared to a use of cash of less than $0.1 million for the prior year. The increase is primarily attributed
to decreased general and administrative costs of $1.3 million when compared to the three months ended March 31, 2012. This includes professional fees of $0.9 million related to the special meeting and change in members of the Board of
Directors, and a retention payment of $0.6 million paid to employees during the major change in senior management. The decreases were partially offset by an increase of $0.3 million of expenses during the three months ended March 31, 2013 due
primarily to transition costs.
As of March 31, 2013, we had cash and cash equivalents of $0.5 million and $7.0 million
of availability on the revolving line-of-credit compared to $2.3 million and $4.7 million, respectively, at December 31, 2012. During the three months ended March 31, 2013, the Company paid down $2.8 million of total debt.
Company will conduct a conference call for investors on Tuesday, May 14, 2013 at 9:00 a.m. Eastern Time to discuss first quarter performance and results. Eric Steen, Chief Executive Officer, and Jonathan P. Foster, Chief Financial Officer, will
discuss the Company s financial performance and answer questions from the financial community. To participate in this call, please dial in toll-free (888) 895-5271 and use the confirmation number 34802235.
About InfuSystem Holdings, Inc.
InfuSystem Holdings, Inc. is a leading provider of infusion pumps and related services to hospitals, oncology practices and other alternate site healthcare providers. Headquartered in Madison
Heights, Michigan, the Company delivers local, field-based customer support and also operates Centers of Excellence in Michigan, Kansas, California, and Ontario, Canada. The Company s stock is traded on the NYSE MKT under the symbol INFU.
Forward-Looking Statements
Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties that could cause actual results to
differ materially from those predicted by such forward-looking statements. These risks and uncertainties include general economic conditions, as well as other risks, detailed from time to time in the Company s publicly filed documents.
Additional information about InfuSystem Holdings, Inc. is available at www.infusystem.com.
FINANCIAL TABLES FOLLOW
INFUSYSTEM HOLDINGS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
March 31, December 31,
(in thousands, except share data) 2013 2012
(Unaudited)
ASSETS
Current Assets:
Cash and cash equivalents $ 472 $ 2,326
Accounts receivable, less allowance for doubtful accounts of $3,601 and $3,136 at March 31, 2013 and December 31, 2012, respectively 9,570 8,511
Inventory 1,378 1,339
Other current assets 832 684
Deferred income taxes 1,986 1,971
Total Current Assets 14,238 14,831
Medical equipment held for sale or rental 2,582 2,626
Medical equipment in rental service, net of accumulated depreciation 13,223 13,071
Property & equipment, net of accumulated depreciation 848 867
Deferred debt issuance costs, net 2,232 2,362
Intangible assets, net 24,871 25,541
Deferred income taxes 17,755 17,806
Other assets 477 419
Total Assets $ 76,226 $ 77,523
LIABILITIES AND STOCKHOLDERS EQUITY
Current Liabilities:
Accounts payable $ 3,056 $ 2,135
Accounts payable - related party 9
Current portion of long-term debt 3,872 3,953
Other current liabilities 4,182 4,098
Total Current Liabilities 11,110 10,195
Long-term debt, net of current portion 24,594 27,315
Total Liabilities $ 35,704 $ 37,510
Stockholders Equity
Preferred stock, $.0001 par value: authorized 1,000,000 shares; none issued
Common stock, $.0001 par value; authorized 200,000,000 shares; issued and outstanding 21,990,000 and 21,802,515, as of March 31, 2013 and December 31, 2012, respectively 2 2
Additional paid-in capital 89,200 88,742
Retained deficit (48,680 ) (48,731 )
Total Stockholders Equity 40,522 40,013
Total Liabilities and Stockholders Equity $ 76,226 $ 77,523
INFUSYSTEM HOLDINGS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
Three Months Ended March 31,
(in thousands, except share data) 2013 2012
(Unaudited)
Net revenues:
Rentals $ 13,445 $ 12,905
Product sales 1,256 1,443
Net revenues 14,701 14,348
Cost of revenues:
Cost of revenues - Product, service and supply costs 2,579 2,235
Cost of revenues - Pump depreciation and loss on disposal 1,699 1,677
Gross profit 10,423 10,436
Selling, general and administrative expenses:
Provision for doubtful accounts 1,660 1,247
Amortization of intangibles 672 684
Selling and marketing 2,408 2,745
General and administrative 5,031 6,273
Total selling, general and administrative: 9,771 10,949
Operating income (loss) 652 (513 )
Other income (loss):
Interest expense (874 ) (601 )
Other income 312 2
Total other loss (562 ) (599 )
Income (loss) before income taxes 90 (1,112 )
Income tax (expense) benefit (39 ) 197
Net income (loss) $ 51 $ (915 )
Net income (loss) per share:
Basic $ 0.00 $ (0.04 )
Diluted $ 0.00 $ (0.04 )
Weighted average shares outstanding:
Basic 21,802,515 21,132,545
Diluted 22,238,160 21,132,545
INFUSYSTEM HOLDINGS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
Three Months Ended March 31,
(in thousands) 2013 2012
(Unaudited)
NET CASH PROVIDED BY (USED IN) OPERATING ACTIVITIES 1,632 (15 )
INVESTING ACTIVITIES
Purchases of medical equipment and property (1,777 ) (2,096 )
Proceeds from sale of medical equipment and property 1,093 925
NET CASH USED IN INVESTING ACTIVITIES (684 ) (1,171 )
FINANCING ACTIVITIES
Principal payments on term loans and capital lease obligations (2,802 ) (2,113 )
Cash proceeds from bank loans and revolving credit facility 2,500
NET CASH USED IN (PROVIDED BY) FINANCING ACTIVITIES (2,802 ) 387
Net change in cash and cash equivalents (1,854 ) (799 )
Cash and cash equivalents, beginning of period 2,326 799
Cash and cash equivalents, end of period $ 472 $
INFUSYSTEM HOLDINGS, INC. AND SUBSIDIARIES
Three Months Ended
March 31,
(in thousands) 2013 2012
Net income (loss) $ 51 $ (915 )
Adjustments:
Interest Expense 874 601
Income Tax Benefit 39 (197 )
Depreciation 1,302 1,445
Amortization 672 684
EBITDA $ 2,938 $ 1,618
Concerned Stockholder Group and Retention 1,466
Stock compensation 458 341
Transition costs 272
EBITDA - Adjusted $ 3,668 $ 3,425
Last updated: May 13, 2013